Navigation Links
FASEB SRC announces conference registration open for: Melatonin Biology: Actions & Therapeutics
Date:2/11/2013

Bethesda, MD The Federation of American Societies for Experimental Biology (FASEB) announces the opening of registration for the Science Research Conference (SRC): Melatonin Biology: Actions & Therapeutics.

The 2013 FASEB SRC on Melatonin Biology: Actions & Therapeutics is an important and unique scientific conference where new and exciting discoveries regarding melatonin as a cytoprotective molecule and a physiological marker of circadian phase will be explored in talks, poster sessions, and intensive scientific discussion. This gathering of researchers from around the world to share cutting edge results and to discuss the functions of melatonin and its receptors in illness and health is key for accelerating breakthrough outcomes in melatonin biology and therapeutics.

FASEB SRC has announced a total of 34 SRCs in 2013. To register for an SRC, view preliminary programs, or find a listing of all our 2013 SRCs, please visit www.faseb.org/SRC.


'/>"/>

Contact: Robin Crawford, CMP
src@faseb.org
301-634-7010
Federation of American Societies for Experimental Biology
Source:Eurekalert

Page: 1

Related biology news :

1. FASEB 2013 Excellence in Science Award recipient announced
2. Undergraduate Student Summer Research Award recipients announced for the 2012 FASEB MARC summer research opportunity program
3. FASEB lauds Air India for transporting research animals
4. FASEB urges biomedical research community to speak out against sequestration
5. FASEB SRC announces conference: Gastrointestinal Tract XV: Epithelia, Microbes, Inflammation & Cancer
6. FASEB SRC announces conference registration open: The Biology of Calpains in Health and Disease
7. FASEB SRC announces: Mechanism and Regulation of Prokaryotic Transcription Conference
8. FASEB SRC announces conference: Renal Hemodynamics: Integrating with the Nephron & Beyond
9. FASEB SRC announces conference registration open for: Ciliate Molecular Biology
10. FASEB SRC announces conference registration open for: Mechanisms in Plant Development Conference
11. FASEB SRC announces conference registration open for: Hematologic Malignancies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: